Status:
UNKNOWN
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Lead Sponsor:
Foundation of Cardiovascular Research and Education Enschede
Collaborating Sponsors:
Abbott Medical Devices
Conditions:
Acute Coronary Syndrome
Angina Pectoris
Eligibility:
All Genders
18+ years
Brief Summary
Drug eluting stents (DES) are widely used for treatment of coronary artery lesions. The Xience Sierra stent has a refined design of the metal stent backbone and is used in patients with various clinic...
Eligibility Criteria
Inclusion
- \>18 years
- requiring PCI and treated with Xience Sierra
- capable of providing informed consent
Exclusion
- known intolerance to components of the study DES or antithrombotic/anticoagulant therapy
- planned elective surgery necessitating interruption of dual antiplatelet therapy (DAPT) \< 3 months
- patient is known to be pregnant, unlikely to adhere to follow-up or expected live \< 1 year
Key Trial Info
Start Date :
September 21 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2025
Estimated Enrollment :
1757 Patients enrolled
Trial Details
Trial ID
NCT04475380
Start Date
September 21 2018
End Date
April 30 2025
Last Update
September 1 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Thoraxcentrum Twente
Enschede, Netherlands
2
Haga Ziekenhuis
The Hague, Netherlands